Tirzepatide research vial
Metabolic

Tirzepatide

A synthetic dual GIP / GLP-1 receptor agonist (research code LY3298176), characterized in preclinical metabolic research.

lyophilized · purity verified by HPLC
$69.99
Quantity
1
COA available on every batch

Customers also frequently order with

Reference only, for laboratory research. Nothing on this page describes use of this material in humans or animals.

What research has studied about Tirzepatide

Tirzepatide is a synthetic peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It has been characterized in published pharmacology studies as a dual incretin-receptor agonist.

Research on tirzepatide has examined how combined GIP and GLP-1 receptor activity affects metabolic signalling in cell and animal models. The observations reported in the literature are laboratory and preclinical findings; nothing here describes human use.

Certificate of Analysis

A representative third-party certificate for Tirzepatide. Every batch ships with a lot-matched COA; contact us for the certificate on any other lot.

Tirzepatide Certificate of Analysis

Specifications

CompoundTirzepatide
Available sizes10 mg, 20 mg, 30 mg
FormLyophilized powder
PurityMeasured by HPLC; see the Certificate of Analysis for the lot
StorageStore cold and away from light per your lab protocol
Intended useLaboratory and research use only
Handling is a bench procedure for a research material. See our guides on how research peptides are reconstituted and how they should be stored.

Research sources

  1. Coskun T, et al., "LY3298176, a novel dual GIP and GLP-1 receptor agonist," Molecular Metabolism 18:3–14 (2018). PMID 30473097
  2. Willard FS, et al., "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist," JCI Insight 5(17):e140532 (2020). PMID 32730231

Frequently asked questions

What is tirzepatide?

Tirzepatide (research code LY3298176) is a synthetic dual GIP and GLP-1 receptor agonist characterized in published preclinical pharmacology studies. Steadfast supplies it as a lyophilized research material for laboratory use only.

What has research studied about tirzepatide?

Published work has characterized its balanced activity at the GIP and GLP-1 receptors in vitro and described metabolic effects in animal models — preclinical observations, not statements about human use.

Is it intended for human use?

No. It is a research chemical for in-vitro laboratory research only, not a drug or supplement.

All Steadfast Research Group products are for laboratory and research use only. Not for human consumption. Not a drug; not intended to diagnose, treat, cure, or prevent any disease. Nothing on this page is medical advice.